Ki-67 gene expression

Sigrid Uxa1,4, Paola Castillo-Binder1,4, Robin Kohler1, Konstanze Stangner1,2, Gerd A. Müller1,3 and Kurt Engeland1,6✉

© The Author(s) 2021

Ki-67 serves as a prominent cancer marker. We describe how expression of the MKI67 gene coding for Ki-67 is controlled during the cell cycle. MKI67 mRNA and Ki-67 protein are maximally expressed in G2 phase and mitosis. Expression is dependent on two CHR elements and one CDE site in the MKI67 promoter. DREAM transcriptional repressor complexes bind to both CHR elements and downregulate the expression in G0/G1 cells. Upregulation of MKI67 transcription coincides with binding of B-MYB-MuvB and FOXM1-MuvB complexes from S phase into G2/M. Importantly, binding of B-MYB to the two CHR elements correlates with loss of CHR-dependent MKI67 promoter activation in B-MYB-knockdown experiments. In knockout cell models, we find that DREAM/MuvB-dependent transcriptional control cooperates with the RB Retinoblastoma tumor suppressor. Furthermore, the p53 tumor suppressor indirectly downregulates transcription of the MKI67 gene. This repression by p53 requires p21/CDKN1A. These results are consistent with a model in which DREAM, B-MYB-MuvB, and FOXM1-MuvB together with RB cooperate in cell cycle-dependent transcription and in transcriptional repression following p53 activation. In conclusion, we present mechanisms how MKI67 gene expression followed by Ki-67 protein synthesis is controlled during the cell cycle and upon induction of DNA damage, as well as upon p53 activation.

INTRODUCTION

The Ki-67 protein is a prominent proliferation marker used in pathology [1, 2]. Ki-67 was first identified as an antigen for a monoclonal antibody detected in the nuclei of proliferating cells [1, 3]. For a long time, the function of this protein remained obscure, even after antibodies directed against Ki-67 were already established tools in cancer diagnostics. The sole relevant feature of Ki-67 was its absence in resting cells and its expression when cells were proliferating [2, 4]. With the establishment of the Ki-67 labeling index, Ki-67 has developed into a standard in diagnosis and prognosis assessment of cancer patients [2]. Complemented by cancer tissue-specific markers, Ki-67 serves as a general indicator for diagnosis and prognosis. The diagnostic procedure for breast cancer with assessment of estrogen receptor, HER2, progesterone receptor, and Ki-67 represents one such example [5].

In contrast to its diagnostic importance, results on the function of Ki-67 were published only recently. The protein is expressed as 320 and 359 kDa isoforms derived from differentially spliced mRNA variants encoded by the human MKI67 gene [2]. Both Ki-67 isoforms serve in a similar function as a surfactant to keep mitotic chromosomes apart after breakdown of the nuclear envelope. By binding to protein phosphatase 1, Ki-67 contributes to the formation of the perichromosomal protein compartment [6]. Furthermore, Ki-67 facilitates chromosome attachment to the mitotic spindle and individual chromosome mobility through covering the surface of chromosomes and creating a membrane-independent intracellular compartment [7]. Through covering chromosomes and forming the perichromosomal region, Ki-67 also contributes to organizing heterochromatin [8]. These Ki-67 features are also responsible for its role in excluding large cytoplasmic molecules such as ribosomes from nuclei that newly form at the end of mitosis [9]. At least in some cell culture systems, depletion of Ki-67 slows down S phase entry [10]. A recent report shows that Ki-67 supports several steps in carcinogenesis [11].

In contrast to the importance of Ki-67 protein expression for cancer diagnostics, only limited information is available on how the MKI67 gene is expressed. It has been shown that the Ki-67 protein is degraded in G1 phase and upon cell cycle exit by the proteasome [12], and that its mRNA is expressed in a cell cycle-dependent manner [13, 14]. Early reports indicated that overexpression of E2F1 could directly or indirectly increase MKI67 mRNA levels [15]. Furthermore, the transcription factor Sp1 was implicated in activating MKI67 transcription [16]. In several meta-analyses of genome-wide chromatin immunoprecipitation (ChiP) data, we have observed that the MKI67 gene is bound by components of the DREAM transcriptional repressor complex [17–19]. DREAM binds to CHR, CDE/CHR, E2F, and E2F/CLE transcription factor-binding sites [20–23]. DREAM contains proteins related to RB (Retinoblastoma tumor suppressor protein, RB or RB1 gene) and members of the E2F transcription factor family, as it is composed of RBL1 (p107) or RBL2 (p130), E2F4 or E2F5, and DP proteins [24, 25]. In addition to these factors, the DREAM repressor complex contains the MuvB core proteins LIN9, LIN37, LIN52, LIN54, and RBBP4 [24, 26]. Functionally, the repressor can turn into a transcription activator by switching the proteins associating with the MuvB core complex to B-MYB and FOXM1 [19, 22, 24, 27–30]. In addition to these observations on DREAM component binding, we also compiled data from many studies showing that MKI67 mRNA is downregulated when the...
transcription factor and tumor suppressor p53 is activated [17–19]. DREAM binding to target promoters and indirect transcriptional repression by p53 are connected through the p53-p21-DREAM pathway [19, 31]. Starting with these initial observations, we analyzed transcriptional regulation of the MKI67 gene.

Here we report that MKI67 mRNA and Ki-67 protein expression during the cell cycle depend on DREAM/MuvB complexes that cooperate with RB. The same cooperation also controls MKI67 and Ki-67 expression in response to p53 activation and upon induction of DNA damage.

MATERIALS AND METHODS

Knockout cell lines

HCT116 wild type (WT), HCT116 p53−/−, and HCT116 p21−/− cells were a generous gift from Bert Vogelstein [32]. NIH3T3 Lin37−/− and NIH3T3 Rb−/−, and NIH3T3 DKO (Lin37/Rb double knockout), as well as HCT116 were performed as described earlier [33]. PCR-based tests for mycoplasma contamination of serum-starved NIH3T3 wt, treated with either 10 µM nutlin-3a (Cayman Chemicals) or 0.2 µg/ml of doxorubicin (Doxo; Medac GmbH) for 48 h. Flow cytometry analyses of serum-starved NIH3T3 wt, Lin37−/−, Rb−/−, and DKO cells have been described earlier [33]. PCR-based tests for mycoplasma contamination were performed as described earlier [35].

Cell culture and drug treatment

Human glioblastoma T98G cells, human epithelial-like immortalized retina hTERT-RPE-1 cells, human immortalized foreskin hTERT-BJ cells, mouse NIH3T3 fibroblasts, human bone osteosarcoma U2OS cells, human colorectal carcinoma HCT116 WT, HCT116 p53−/−, and HCT116 p21−/− cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM; Lonza). DMEM was supplemented with 10% fetal calf serum (FCS; Biochrom) and 1% penicillin/streptomycin (Sigma-Aldrich). Standard growth conditions with 37°C and 10% CO2 were chosen. For serum starvation, FCS was removed from the medium for 72 h. For restimulation, 20% FCS were added to the medium. For p53 activation, the cells were treated with either 10 µM nutlin-3a (Cayman Chemicals) or 0.2 µg/ml doxorubicin (Doxo; Medac GmbH) for 48 h. Flow cytometry analyses of serum-starved NIH3T3 wt, Lin37−/−, Rb−/−, and DKO cells have been described earlier [33]. PCR-based tests for mycoplasma contamination were performed as described earlier [35].

Sequence alignment and ChIP tracts

The UCSC Genome Browser database was employed to retrieve and align genomic sequences [36]. To analyze published ChIP data, we searched the ENCODE database and compared profiles using the UCSC Genome Browser [36, 37]. To compare different ChIP-sequencing tracks and different genome loci, the vertical viewing ranges were consistently set to a minimum of 0 and a maximum of 20.

Flow cytometry

DNA content of propidium iodide-stained cells was analyzed by flow cytometry (LIS II, Becton Dickinson) as described before [20]. The software Flowjo (Becton Dickinson) was used for cell cycle phase analysis.

Semi-quantitative real-time PCR and transcription start site mapping

Total RNA was isolated using TRIzol Reagent (ThermoFisher Scientific) according to the manufacturer’s protocol. Reverse transcription and quantitative PCR were combined in a one-step quantitative PCR (qPCR) reaction using the Quantitect SYBRGreen PCR Kit (Qiagen). Samples were measured on an ABI 7300 Real-Time PCR System (Applied Biosystems). All primer sequences are listed in Suppl. Table 1.

SDS-PAGE and western blotting

For SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, standard in-house protocols were followed as described earlier [38]. For protein detection, the following antibodies were employed: Ki-67 (MIB1, DAKO), β-Actin (A5451, Sigma-Aldrich), LIN37 (T3, custom-made at Pineda Antikörper-Service, Berlin, Germany) [39], LIN54 (A303-799A, Bethyl Laboratories), LIN9 (ab62329, Abcam), p130 (RBL2, D97T7M, Cell Signaling Technologies), KIF23 (MKLP-1, sc-136473; Santa Cruz Biotechnology), p53 (Ab-6, DO-1; Merck/Calbiochem), p21 (Ab-1, EA10; Merck/Calbiochem), E2F1 (C-20, sc-193; Santa Cruz Biotech.), E2F2 (A300-766A, Bethyl Laboratories), E2F4 (C-20, sc-866; Santa Cruz Biotech.), RB (D20, No. 9313; Cell Signaling Technologies), and NF-YA (G-2, sc-17753; Santa Cruz Biotech.). The monoclonal B-MYB LX015.1 antibody (hybridoma media 1:5) was a kind gift from Roger Watson.

Protein quantification from western blottings was performed with the Labimage 1D software (Kapelan Bio-Imaging, Leipzig, Germany).

Plasmids

A 596 bp-long promoter region of the MKI67 gene was amplified from human genomic DNA extracted from HFF cells and cloned into the pGL4.10 vector backbone. Site-directed mutation of promoter elements was performed by following the QuickChange Site-Directed Mutagenesis protocol (Stratagene). All primers are listed in Suppl. Table 1. Expression plasmids for Lin37 and Rb were described earlier [33, 40]. The plasmid for expression of a short hairpin RNA (shRNA) targeting mouse B-Myb was a kind gift from Kenneth Boheler (pSuper.neo, Oligoengine; target sequence: 5′-GGTGCAGACCTGAGTAAAT-3′) [41]. As a control, a plasmid expressing an shRNA-targeting green fluorescent protein (pSuper.neo; target sequence 5′-GGTGTGTCAGTGGAGAG-3′) was created.

Luciferase promoter reporter assays and siRNA transfections

Luciferase reporter assays were performed with extracts of transfected synchronized NIH3T3 or RPE-1 cells as described before [20]. Twenty-four hours post transfection with Genejuice (EMD Millipore), cells were washed twice with phosphate-buffered saline and DMEM w/o FCS was added. For rescue experiments, Lin37−/−, Rb−/−, and Lin37−/− Rb−/− (DKO) NIH3T3 cells were plated in 12-well plates (25,000 cells per well) and transfected with 150 ng of promoter reporter plasmids along with 200 ng of constructs expressing WT Lin37 and Rb. To analyze the response of the MKI67 promoter reporter constructs to knockdown of B-Myb, NIH3T3 cells were plated in 24-well plates at a density of 12,500 cells per well. Each well was transfected with 100 ng promoter reporter construct, 200 ng shRNA-expressing plasmids, 20 ng pGL4.70[hRluc] (Promega), and 1 µl FuGENE (Promega). Cells were collected 48 h post transfection.

To analyze the response of the MKI67 promoter reporter constructs to B-Myb knockdown, cells were transfected with 100 ng promoter reporter construct, 40 ng pGL4.70[hRluc] (Promega), as well as 0.8 µl DharmaFECT Duo (Dharmacon, Inc.), plated in 24-well plates at a density of 25,000 cells per well. After 24 h, medium was changed and cells were transfected with 10 nM or 25 nM small interfering RNA (siRNA) (ON-TARGETplus Human MYBL2 SMARTPool siRNA and ON-TARGETplus Non-targeting Control Pool; from Dharmacon, Inc.) and 0.75 µl Lipofectamine RNAiMAX (ThermoFisher). Cells were collected 24 h post siRNA transfection.

DNA affinity purification

DNA affinity purification assays were performed as described earlier [20, 42]. Briefly, biotinylated DNA probes were amplified via PCR from respective promoter reporter pGL4.10 plasmids. All primer sequences and plasmids are listed in Suppl. Table 1. DREAM and MMB complex components were purified from nuclear extracts from serum-starved T98G or NIH3T3 cells, or from proliferating HeLa cells with the biotinylated DNA probes. Bound proteins were separated by SDS-PAGE and detected by western blotting.

Chromatin immunoprecipitation

ChIP assays were described earlier [23, 43]. The following antibodies were used to precipitate DREAM, MM2, and E2F complex components: E2F4 (C-20, sc-866; Santa Cruz Biotech.) [44], E2F1 (C-20, sc-193; Santa Cruz Biotech.), E2F2 (C-20, sc-633; Santa Cruz Biotech.), E2F3 (C-18, sc-878; Santa Cruz Biotech.), LIN37 (T1, custom-made at Pineda Antikörper-Service, Berlin, Germany), MMYB (N-19, Santa Cruz Biotech.), FOXM1 (C-20, sc-502, Santa Cruz Biotech.) [33], and NF-YA (G-2, sc-17753; Santa Cruz Biotech.). The E2F3 antibody was directed against the C terminus of the protein and did not distinguish between E2F3A and E2F3B, which differ in their N-terminal domain [45]. As a negative control for the ChIP experiments, rabbit IgG was used (Rabbit IgG isotype control, No. 02-6102; ThermoFisher Scientific).

RESULTS

Ki-67 is maximally expressed in G2 phase and mitosis

We measured MKI67 mRNA expression in synchronized human T98G and hTERT-BJ cell lines, as well as in mouse NIH3T3 cells (Fig. 1A). Serum-starved cells were released from the G0/G1 arrest...
into S phase. The maximum of expression is reached in G2/M phases (Fig. 1A). To stimulate the cells to re-enter the cell cycle, FCS was added to the medium. Cells were collected every 3 h after serum restimulation. Each sample was divided into three aliquots for RNA and protein extraction, and for flow cytometry analyses. Relative mRNA levels from MKi67/Mki67 genes were quantified using real-time RT-qPCR. Mean values ± SD of two technical replicates for each time point are given. The maximum fold-change in MKi67/Mki67 mRNA levels was calculated for each cell line. Approximations of cell cycle phase distribution for hTERT-BJ cells were deduced from flow cytometry analyses in C and are indicated above the graphs. B Protein levels of Ki-67 in hTERT-BJ cells used in A, B, and C over the course of one cell cycle were analyzed by western blot analysis. One representative experiment from three biological replicates is shown. KIF23 and β-actin proteins served as cell cycle and loading controls, respectively. Approximate cell cycle phases are indicated. C Flow cytometry analyses of propidium iodide (PI) staining of hTERT-BJ cells analyzed in A and B. Quantification of Ki-67 protein expression of two biological replicates is displayed in Suppl. Fig. 1.

by serum addition and were collected at several time points during the cell cycle. In all cell lines analyzed, the mRNA levels in G0/G1 are low and begin to rise in late G1 phase and with entry into S phase. The maximum of expression is reached in G2/M phases (Fig. 1A).

Next, we measured Ki-67 protein levels in resting hTERT-BJ cells and from cell populations enriched in the different phases of the cell cycle (Fig. 1B, C and Suppl. Fig. 1). The expression of Ki-67 protein was not detectable for the first 18 h following restimulation of cells to enter the cell cycle. The protein was initially detected after 21 h of restimulation, corresponding to S phase. Ki-67 protein levels reached maximal expression at about 30 h, with most cells in G2 phase or mitosis. Ki-67 protein followed MKi67 mRNA expression, lagging by about 5 h. Expression of the KIF23 protein served as a positive control for cell cycle-dependent expression (Fig. 1B). KIF23 is an established DREAM-CHR target gene with an expression maximum in G2/M [46].

Identification of phylogenetic conserved putative regulatory sites and the transcription start in the MKi67 gene

We were interested in elucidating how transcription of the MKi67 gene is regulated. As phylogenetic conservation can locate important regulatory DNA segments, we searched the MKi67 promoter for conserved potential transcription factor-binding sites. Analysis of the region upstream of MKi67 exons with the UCSC Genome Browser yielded several conserved elements (Fig. 2). We mapped the transcription start site (TSS) to the 5′-end of the UTR-1 transcript, which begins just downstream of the conserved region (Suppl. Fig. 2). Also, there is no conserved TATA-box in the MKi67 upstream region (Fig. 2), which is often observed in promoters of cell cycle genes [21].

Interestingly, two CHR elements are conserved in the MKi67 upstream region (Fig. 2). This is unprecedented, as functional CHR sites have been discovered so far only as single elements [23]. Both MKi67 sites are identical with the canonical CHR sequence 5′-TTTGAAGA-3′ [23]. CHRprox, the site found proximal to the coding region, is localized 12 nucleotides downstream from the distal element (CHRdist). Upstream of CHRdist and separated by a four-nucleotide spacer, a conserved CDE site is located. Overlapping with the CDE, an element similar to an E2F site is conserved [47].

Furthermore, we identified three conserved CCAAT-boxes [48]. CCAAT1 and CCAAT3 are oriented in reverse orientation relative to the TSS (Fig. 2). With the sequence 5′-TCAAT-3′, CCAAT2 deviates from the consensus for binding of NF-Y [48]. CCAAT1 overlaps by one nucleotide with CHRprox (Fig. 2).

A 596 bp DNA fragment comprising evolutionary conserved transcription factor-binding sites can direct cell cycle-dependent transcription of the MKi67 gene

We tested by luciferase reporter assays whether a 596 bp DNA fragment of the MKi67 gene can serve as its promoter and mediate cell cycle-dependent transcription (Fig. 3). This fragment included the TSS and all identified conserved elements (Fig. 2 and Suppl. Fig. 2).

We assayed the WT MKi67 promoter for expression in resting NIH3T3 cells and during progression through the cell cycle. Activity of the MKi67 upstream region is low in G0 and in G1 phases. However, the MKi67 region controls increasing expression of the reporter in S phase, reaching maximum expression when cells progress into G2 phase and mitosis (Fig. 3A). This expression pattern is reminiscent of the MKi67 mRNA expression (Fig. 1A). Therefore, the data suggest that the 596 bp segment serves as the promoter of the MKi67 gene.

Two CHR sites and one CDE control MKi67 cell cycle-dependent transcription

Next, we introduced mutations into the CHRdist, CHRprox, and CDE sites to generate the 3mut construct. These combined mutations led to a complete deregulation of cell cycle-dependent
promoter activity (Fig. 3A). Although the activity of the WT MKI67 promoter construct was low in G0 cells, luciferase expression controlled by the 3mut construct was already at a high level. This expression level remained essentially the same throughout the cell cycle for the 3mut reporter, whereas in the same experiment the WT promoter directed the typical cell cycle-dependent expression (Figs. 1B and 3A). The deregulation in the 3mut construct also led to a lower maximal expression in G2 phase and mitosis when compared to the WT reporter (Fig. 3A). Taken together, the results suggest that the combination of two CHR elements and a CDE site are responsible for directing cell cycle-dependent transcription of the MKI67 gene.

A more detailed analysis with individually mutated sites revealed the contribution of single elements. We compared the activities in G0 vs. G2/M cells of the WT MKI67 promoter with the activities of various mutant promoters in NIH3T3 cells (Fig. 3B, C). None of the individual mutations of the CHRprox, CHRdist, and CDE sites led to the nearly total loss of regulation that was observed with the triple-mutant 3mut construct. Even combined mutation of two of the three relevant sites in the 2CHRmut and CDE/CHRdist constructs did not yield a complete loss of regulation (Fig. 3B, C). In summary, these results show that the CHRprox, CHRdist, and CDE sites can largely substitute for each other.

However, there is one aspect in which they cannot function alternatively. Promoter constructs with mutations in CHR elements only reached lower maximal activities in G2/M cells than their WT and CDE mutant counterparts (Fig. 3A, B). This observation is consistent with transcriptional activation by FOXM1/B-MYB/MuvB complexes through CHR sites, which do not require binding to CDE or E2F elements [39].

Mutation of the three CCAAT-boxes individually and in combinations did not significantly alter cell cycle-dependent transcription from the MKI67 reporter. Only the overall activity from the promoter reporter decreased upon mutation of CCAAT-boxes (Suppl. Fig. 3).

In summary, the combination of CHRdist, CDE, and CHRprox is responsible for cell cycle-dependent transcription of the MKI67 promoter.

DREAM, E2F, and FOXM1/B-MYB/MuvB complex components bind to the MKI67 promoter in vivo and in vitro

After identifying the regulatory sites in the MKI67 gene, we investigated protein binding to the promoter. In vivo binding was assayed by ChIP in T98G cells synchronized in G0 or G2/M (Fig. 4A). We found that E2F4, E2F1/2/3, LIN37, B-MYB, FOXM1, and NF-YA bind to the MKI67 promoter region.

E2F4, representing the DREAM repressor complex, bound significantly in G0 cells, but only weakly in G2/M cells. In contrast, the activating transcription factors E2F1/2/3, B-MYB, and FOXM1 displayed elevated binding to the MKI67 promoter in later phases of the cell cycle but low binding in resting cells (Fig. 4A). Consistent with its role in both repressing and activating MuvB complexes, LIN37 bound similarly well in resting and G2/M cells. NF-YA is a subunit of the hetero-trimeric transcriptional activator NF-Y, which binds CCAAT-boxes [48]. In ChIP assays, we observed that binding of NF-YA in resting vs. G2/M cells was not substantially different (Fig. 4A). Taken together with the result that MKI67 CCAAT-boxes have only a small impact on cell cycle regulation (Suppl. Fig. 3), these observations indicate that NF-Y binding to CCAAT-boxes does not substantially contribute to cell cycle-dependent regulation of MKI67.

In conclusion, the results from the ChIP experiments are consistent with downregulation of MKI67 by DREAM in resting cells and activation by MuvB/B-MYB/FOXM1 in later cell cycle phases.
DREAM/MuvB complexes bind to both CHR sites in the MKI67 promoter

To test for differences in protein binding to WT and mutant MKI67 promoters, DNA affinity purifications were performed (Fig. 4B–F). Nuclear extracts derived from proliferating HeLa cells, density-arrested human T98G cells, restimulated T98G cells, serum-starved mouse NIH3T3 cells, as well as restimulated NIH3T3 cells were employed. Serum-starved or density-arrested cells are largely in G0, which allows for binding analysis of DREAM components. In contrast, HeLa cells do not form DREAM or E2F/RB repressor complexes due to the expression of the human papilloma viruses E7 protein, which binds RB, p107, and p130 [43, 49, 50]. However, HeLa cells assemble activator MuvB complexes with B-MYB.

LINS4 and LIN37 proteins were analyzed as indicators for all MuvB-derived complexes. In all assays, binding of LINS4 and LIN37 dropped to the level of the negative control when both CHR sites...
were destroyed as with the 2CHRmut and 3mut probes (Fig. 4B–F). However, mutation of a single site as in the CHRprox and CHRdist probes still allowed for binding of the MuvB proteins. Binding of the DREAM components E2F4 and p130 was also lost when both CHR sites were mutated, and the same observation was made for B-MYB as a component of activator MuvB complexes in HeLa cells (Fig. 4B–F). As expected, binding of p130 was not detected when the DNA probes were incubated with HeLa extracts. This is in line with the fact that these cells do not form DREAM (Fig. 4B) [50]. Together, the results indicate that the two CHR sites can independently bind repressing and activating MuvB complexes.

Importantly, binding of E2F1, as a representative of the activator
E2Fs is not altered substantially upon CDE mutation (Fig. 4B–D). This indicates that the CDE site is not overlapping with a functional E2F element, which was a possibility brought up by sequence comparison (Fig. 2). In addition, there is also no significant loss of E2F1 binding upon mutation of the CHRprox and CHRDist sites, which are the key cell cycle elements (Fig. 4B–D).

These results suggest that the activating E2Fs do not bind through the elements that are required for cell cycle regulation.

Another important aspect to evaluate a potential function of activator E2Fs in transcriptional repression of Mki67 is binding of their complexing partner RB. We searched the ENCODE database for RB (RB1) ChIP binding. There is only background binding of RB to the Mki67 promoter, whereas some binding is detected at the MYBL2 gene (Suppl. Fig. 4B, C). In the database entry, substantial and consistent binding of EF2F4, FOXM1, and B-MYB to the regulatory region of the Mki67 promoter is observed (Suppl. Fig. 4B, C).

In regard to function of the transcriptional activator complex NF-Y, in vitro binding of NF-YA displayed only small changes for the Mki67 promoter mutants tested (Fig. 4B–F), which is consistent with the notion that NF-Y binds to CCAAT-boxes. As a secondary aspect, NF-Y binding can therefore serve as loading control for the experiments (Fig. 4B–F).

In summary, the in vitro data show that MuvB complexes bind through individual CHRDist and CHRprox elements independent of the respective other element. In resting cells, both CHR sites can bind DREAM; in later cell cycle phases, they bind MuvB/B-MYB/FOXM1 complexes. In contrast, RB and E2F1, as a representative of activator E2Fs, do not bind to the regulating CHR and CDE sites. These in vitro results are supported by in vivo ChIP data.

**B-MYB activates the Mki67 promoter through the two CHR elements**

Next, we tested whether binding of B-MYB correlates with Mki67 gene activation. In HCT116 and U2OS cell lines, siRNA-directed knockdown of B-MYB yielded a >50% drop in Mki67 mRNA expression (Fig. 5A, B). Further, B-MYB knockdown substantially reduced WT Mki67 promoter activity, whereas a reporter mutated in the CHRDist, CHRprox, and CDE sites (3mut) was not affected (Fig. 5C). In addition, transactivation of WT and individual mutant Mki67 promoter reporters was assayed when B-MYB had been knocked down by shRNAs expressed from cotransfected plasmids (shB-Myb) (Fig. 5D). We found that activity of the WT promoter drops to about one-third in the shB-Myb-treated cells. This effect was lost when both CHR sites were mutated, because the level of activity from those mutant promoters was reduced to about the level of the B-MYB knockdown experiments. In contrast, single mutation of CDE, CHRprox, and CHRDist sites showed the elevated levels of activity. These levels were reduced upon B-MYB knockdown (Fig. 5D).

These results show that both CHR elements are required for full transcriptional activity of the Mki67 promoter. Furthermore, B-MYB binding to the CHR sites correlates with B-MYB-dependent activation through the two CHR elements.

**DREAM cooperates with RB for maximum repression of Mki67 gene expression**

In experiments employing several knockout cell models, we had shown that DREAM and RB display partially overlapping functions in cell cycle-dependent gene regulation [33, 34]. We had observed that deletion of the DREAM component LIN37 selectively leads to loss of repression by DREAM but does not hamper activation through MuvB complexes [33]. Thus, we were interested in elucidating whether RB also has an influence on DREAM-dependent control of Mki67 expression.

We tested Mki67 mRNA expression at different time points after serum starvation in WT NIH3T3 mouse fibroblast and knockout cells deficient in LIN37, Rb, or in both LIN37 and Rb (DKO) (Fig. 6A).

In WT cells, Mki67 mRNA expression was low in serum-starved and restimulated cells for up to 10 h in which cells are mostly in G0 and G1 phases, respectively. Expression increased in S phase, reaching its maximum in G2/M (Fig. 6A). In RB-knockout cells, this expression pattern was similar, but with a small increase in serum-starved cells and a decrease in expression at later restimulation time points, respectively. A more pronounced deregulation was observed in serum-starved LIN37-knockout cells, indicating that DREAM function is more important to repress the Mki67 promoter in serum-starved cells than RB function (Fig. 6A).

Importantly, the Mki67 mRNA regulation was largely lost, in particular at early time points, in cells deficient for both RB and LIN37/DREAM. Still, over the time course, some regulation was observed in the double-knockout cells. However, the substantial deregulation in DKO cells is particularly obvious when focusing on the results for the 0 and 18 h time points (Fig. 6A). In conclusion, both RB and LIN37/DREAM are important for cell cycle-dependent transcription of Mki67. LIN37/DREAM appears to have a larger impact than RB.

In addition, we performed rescue experiments in the knockout cell lines with Mki67 promoter reporter assays as readout. We compared regulation of the WT promoter with the 3mut construct, which carries mutations in the two CHR elements and the CDE site. Re-expression of LIN37 and RB in serum-starved NIH3T3 DKO cells deficient for the two proteins re-established repression of the reporter to a large extent (Fig. 6B). Single rescue experiments by re-expressing LIN37 or RB alone had some effect compared to the empty vector transfection control experiment. Here again, the effect exerted by LIN37/DREAM appears to be larger than that of RB (Fig. 6B). The rescue experiments with re-establishing DREAM and RB/E2F function tested by reporter assays suggested that both protein complexes are required for Mki67 promoter downregulation through two CHR elements and one CDE site.

Taken together, results from the knockout cell systems indicate that particularly in G0 cells, lack of DREAM function has a stronger effect than deletion of RB on the repression of Mki67. Furthermore, the experiments show that LIN37/DREAM and RB cooperate in downregulating Mki67 expression.

**Ki-67 downregulation after DNA damage and p53 activation depends on the p53-p21 pathway**

Following DNA damage, transcriptional repression via the p53-p21-DREAM pathway for genes carrying single CHR elements in their promoters is well established [18, 34]. However, as the Mki67 gene involves two CHR sites and is also regulated by RB, we examined the effect of p53 and p21 (CDKN1A) induction on Mki67 expression. To test for regulation by the p53-p21 pathway, we treated human colon carcinoma HCT116 WT, p53-deficient, or p21-deficient cells with Doxo or nutlin-3a to activate p53 signaling (Fig. 7A). In WT cells, Mki67 mRNA expression was downregulated. However, in p53−/− or p21−/− cells, Mki67 downregulation was lost (Fig. 7A). This Mki67 mRNA pattern is mirrored in Ki-67 protein levels (Fig. 7B). These results show that downregulation of Ki-67 following DNA damage or p53 stabilization requires both p53 and p21. Therefore, Ki-67 appears to be regulated by the p53-p21 pathway.

**LIN37 and RB contribute to Mki67 mRNA downregulation upon DNA damage induction and p53 activation**

After finding that Ki-67 expression is controlled by the p53-p21 pathway, we tested whether this regulation depends on RB or LIN37/DREAM. We tested Mki67 and CDKN1A/p21 mRNA expression after nutlin-3a or Doxo treatment in HCT116 WT and RB−/−, LIN37−/−, or LIN37−/−; RB−/−; or mutant cells (Fig. 8). All cell lines tested were positive for WT p53 [51]. Consistently, stabilization of p53 by nutlin-3a or induction of DNA damage by Doxo, respectively, led to a substantial induction of CDKN1A/p21 mRNA in all cells.
MKI67 mRNA was downregulated in WT cells by both treatments. Importantly, MKI67 mRNA repression was completely lost in LIN37−/−; RB−/− double-mutant cells upon p53 stabilization or DNA damage induction (Fig. 8). When treated with nutlin-3a, MKI67 mRNA downregulation was reduced in RB-deficient cells and even more attenuated in cells deficient in Lin37/DREAM. Upon Doxo treatment, MKI67 mRNA expression in LIN37−/− was still downregulated compared to WT cells, but to a lower extent. Different from the nutlin-3a treatment, incubation with Doxo did not alter MKI67 mRNA levels in RB−/− cells significantly compared to the untreated sample (Fig. 8). These observations show that HCT116 RB−/− cells respond differently with MKI67 mRNA downregulation upon nutlin-3a or Doxo treatment. Taken together, downregulation of MKI67 mRNA following DNA damage or p53 stabilization depends on intact DREAM and RB.

Fig. 5 B-MYB activates the MKI67 promoter through the two CHR elements. A, B MKI67 mRNA expression after B-MYB knockdown in HCT116 (A) or U2OS (B) cells. The cells were transfected with A 10 nM or B 25 nM non-targeting siRNAs (siCtrl) or B-MYB siRNA (siB-MYB). Relative mRNA levels from MKI67 and MYBL2 genes were quantified using real-time RT-qPCR. Mean values ± SD of three (A) or four (B) biological replicates are given. C MKI67 luciferase promoter reporter assays after B-MYB knockdown in U2OS cells employing wild-type (wt) and mutant MKI67 promoter (3mut) carrying mutations in the CHRprox, CHRdist, and CDE sites. Mean values ± SD are given of one representative experiment with three technical replicates out of four biological replicates. D NIH3T3 cells were transfected with MKI67 luciferase promoter reporter constructs together with equal amounts of plasmids expressing non-targeting shRNAs (shGFP) or B-Myb shRNAs (shB-Myb). Transfected reporter plasmids were the empty reporter vector pGL4.10 (vector control) and wild-type or mutant reporter plasmid constructs: wild-type (wt), mutants of the proximal CHR (CHRprox), distal CHR (CHRdist), mutant of both CHR elements (2CHRmut), CDE mutant (CDE), a combination of mutations in CHRdist and CDE (CDE/CHRdist), and mutation of the three sites CHRprox, CHRdist, and CDE (3mut). The mean relative light units (RLUs) of two biological replicates and SDs are given.
Cell cycle-dependent expression is the characteristic feature of the Ki-67 protein. Since its discovery, detection of Ki-67 has served as the indicator for proliferating cells [1–4, 52].

Ki-67 protein levels are low or absent in G0 and G1 phases, and Ki-67 accumulates during S, G2, and M phases [53, 54]. Low levels of Ki-67 in G0 and G1 phases were shown to depend on the timespan that cells have spent in G0. Proteasomal degradation has been found to be responsible for Ki-67 loss at the end of mitosis and during G0 and G1 phases [8, 12, 54]. Importantly, persistent low levels of Ki-67 after G0 entry can serve as an indicator for quiescence. Cancer cells, in contrast to normal cells, spend less time in phases between mitosis and re-entering S phase. Therefore, low levels relative to non-detectable Ki-67 expression in G0 or G1 phases are one indicator of...
prognosis in malignant diseases [5, 54]. These subtle differences are not detected by standard immunohistochemistry, but more advanced methods allow Ki-67 to become an even better marker of quiescence and proliferation [54].

Although Ki-67 protein expression during the cell cycle has been well studied, reports on transcription and mRNA expression from the *MKI67* gene are limited. Here we show that *MKI67* mRNA expression precedes the appearance of Ki-67 protein with a short lag phase and with similar kinetics (Fig. 1). In reporter assays, we demonstrate that the corresponding kinetics are observed when transcription from the *MKI67* promoter in the cell cycle is examined (Fig. 3). Thus, these results imply that expression of *MKI67* mRNA and subsequent synthesis of Ki-67 protein are dependent on transcriptional regulation from the *MKI67* promoter.

A detailed functional analysis of conserved promoter elements identified two CHR sites responsible for cell cycle-dependent transcription, one of them as part of a CDE/CHR tandem element. Only mutation of all three sites resulted in a near-complete deregulation, indicating that the regulatory elements can in part substitute for each other (Fig. 3). Such a combination of two putative CHR elements is found rarely in G2/M-expressed genes and the combination of two functional CHR sites in tandem has not been observed before [21, 23, 39].

With the unusual combination of elements, we also observed unexpected combinations of protein binding to the *MKI67* promoter. We showed binding of DREAM/MuvB, B-MYB, and FOXM1 proteins in ChIP assays and in vitro binding experiments through the two CHR sites (Fig. 4 and Suppl. Fig. 4). B-MYB and FOXM1 bind to the MuvB core complex [27, 29]. Importantly, we observe a correlation between B-MYB binding and its function as transactivator. B-MYB-dependent activation requires the two CHR sites in the *MKI67* promoter, which are also required for B-MYB binding (Figs. 4 and 5). Complexes of FOXM1 and B-MYB with MuvB bind DNA through the MuvB component LIN54 and transactivate target genes [20, 55, 56] (Fig. 9). Consistent with the model that MuvB-derived complexes activate *MKI67* transcription through CHR elements, it was reported that expression of Ki-67 as a fusion with a fluorescent protein from endogenous genes was decreased when B-MYB is knocked down [54]. Furthermore, a recent report showed that *MKI67* mRNA is downregulated when FOXM1 is knocked down [57].

In addition to factors regulating through CHR sites, we also found differential binding of the activator E2F proteins E2F1/2/3 by ChIP (Fig. 4). Yet, there are no E2F sites in the *MKI67* promoter and E2F transcription factors are unable to bind through CHR elements [23]. In general, CDE sites are intrinsically related to E2F elements, as they
complexes with RB [30]. Therefore, we also examined a potential

MKI67 gene [60]. E2F4 and E2F5, as components of DREAM, can interact with CDE sites, while DREAM attaches to CHR sites with its LIN54 component [39, 61] (Fig. 9).

To elucidate the functional interaction between RB and DREAM, we employed our RB and Lin37-knockout cell models [33, 34]. Deletion of Lin37 abrogates repressor function of DREAM [33]. We observed that mutation of RB led to a moderate deregulation of cell cycle-dependent Mki67 mRNA expression when expression levels in serum-starved vs. restimulated cells were compared (Fig. 6A). RB-negative cells display an Mki67 mRNA regulation similar to the WT cells in serum-starved cells. Thus, particularly when comparing regulation in G0 cells, Lin37 single mutation caused a larger Mki67 mRNA deregulation than the RB mutation. Importantly, mutation of both genes resulted in a substantial loss of regulation. Rescue experiments in serum-starved cells with re-expression of RB and Lin37 in double-knockout cells also supported the conclusion that both proteins are required for regulation (Fig. 6). These results show that transcriptional repression of Mki67 depends on DREAM and RB.

Taken together, all observations are consistent with a model in which MuvB complexes together with RB cooperate in controlling Mki67 cell cycle-dependent transcription (Fig. 9). DREAM represses transcription in G0 and G1 phases. Mki67 downregulation by DREAM is indirectly supported by RB. Starting in S phase, repression of Mki67 transcription is lost when p107/p130, E2F4/5, and DP dissociate from DREAM/MuvB. Later in the cell cycle, B-MYB or FOXM1 sequentially bind to MuvB, to form the B-MYB-MuvB or FOXM1-MuvB complexes (Fig. 9). These two complexes can activate Mki67 transcription through two CHR sites in the Mki67 promoter [19, 20, 27, 30].

Another aspect of Mki67 transcriptional control is the downregulation of Ki-67 by the tumor suppressor p53 [62]. We showed that indirect p53-dependent downregulation of Mki67 mRNA and Ki-67 protein requires the cyclin-dependent kinase (CDK) inhibitor p21 (CDKN1A) (Fig. 7). Thus, Ki-67 is a target of the p53-p21-DREAM pathway leading to cell cycle arrest [19, 31]. According to this pathway, p53 activates transcription of CDKN1A/p21. The p21 protein then inhibits CDKs that phosphorylate RB family proteins. Members of this family are RB, as well as p107 (RBL1) and p130 (RBL2). Hypophosphorylated p107 or p130 proteins are required to form DREAM. Thus, the p53-p21-dependent formation of DREAM and RB-E2F complexes ultimately downregulates many genes indirectly repressed by p53 [34]. In this large group, Ki-67 downregulation is part of a concerted regulatory program to block the cell cycle through RB and the p53-p21-DREAM pathway [19-25].

We had previously collected data from genome-wide ChIP studies showing that DREAM complex components bind to Mki67 [17, 18]. Furthermore, meta-analyses yielded that Mki67 mRNA is downregulated upon p53 induction in several cell systems [17, 18, 59]. These studies also established that p53 protein does not bind to the Mki67 gene. In contrast to these observations, it was speculated that binding of Sp1 to p53, resulting in tethering of p53 to Sp1 sites in the Mki67 promoter, may contribute to repression [63]. However, a tethered Sp1-p53 complex at the Mki67 promoter is not consistent with the many p53 ChIP experiments, proving that p53 is neither directly nor indirectly bound to the Mki67 gene [17, 18, 59].

Whether Ki-67 affects the cell cycle has been discussed controversially [10]. Proliferation of cells lacking Ki-67 is largely normal and knockout mice show normal development. However, when exposed to several stresses, Ki-67-knockout cells proliferate less than their WT counterparts [7]. Ki-67 depletion by siRNA causes slower S phase entry compared to untreated cells, results in an increase in p21 (CDKN1A) mRNA, and leads to downregulation of G1/S genes. Thus, a model was developed that connects downregulation of Ki-67 with an increase in p21, yielding a downregulation of G1/S genes, which causes a delay in S phase entry [10]. With our current results, we show that Ki-67 is also a target for downregulation by p21. This observation suggests an amendment to the cell cycle control model by a positive feedback

**Fig. 8** LIN37 and RB contribute to Mki67 mRNA downregulation upon DNA damage induction and p53 activation. HCT116 wild-type (WT) and mutant cells were tested for mRNA expression of the Mki67 and the CDK inhibitor CDKN1A/p21 genes. Clonal cell lines for WT (n = 4), RB−/− (n = 3), LIN37−/− (n = 4), or double-knockout LIN37−/−; RB−/− (n = 2) cells were treated with nutlin-3a or doxorubicin for 48 h. As controls, untreated or DMSO (solvent control)-treated (48 h) cell lines were analyzed. Levels of mRNA from CDKN1A/p21 and Mki67 genes were determined by real-time RT-qPCR. The log2-fold changes in mRNA expression of treated vs. control cells are given. Mean values are indicated by black bars. Significances were calculated using the Student’s t-test (n.s., not significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).

support DREAM binding to CHR sites through binding of the E2F4/S-DP components of DREAM [21, 39]. The CDE upstream of CHRD1st overlaps in forward and reverse orientations with a sequence that is close to the E2F-binding consensus (Fig. 2) [47]. However, the activator E2F1 does not bind to this element (Fig. 4).

To contribute to transcriptional repression in G0 as observed for Mki67 expression (Figs. 1 and 6), E2F1/2/3 factors need to form complexes with RB [30]. Therefore, we also examined a potential binding of RB to Mki67. However, neither significant binding in vitro to the CDE and CHR elements nor in vivo to the Mki67 promoter region was observed for RB (Fig. 4 and Suppl. Fig. 4). It is therefore likely that RB does not form complexes with E2F proteins to bind to the Mki67 promoter to affect Mki67 expression. Nevertheless, RB has an impact on Ki-67 expression. Thus, we suggest an indirect mechanism that is independent of RB/E2F binding to the Mki67 gene (Fig. 9). RB can affect cell cycle regulation without binding to E2F promoter sites and without complex formation with activating E2F transcription factors by several mechanisms [25]. Such mechanisms that link RB to the expression or regulation of DREAM components can be phosphorylation, acetylation, ubiquitination, or complex formation of DREAM/MuvB factors as examples. One such functional link between RB and DREAM is exemplified by the RB-LATS2-DYRK1A-LIN52/DREAM axis [58].

In regard to binding of DREAM/MuvB, B-MYB, and FOXM1 proteins, we find binding of the DREAM components E2F4, LIN37, p130, and LIN54, as well as binding of the MuvB-associated factors B-MYB and FOXM1 to the Mki67 promoter (Fig. 4 and Suppl. Fig. 4). In general, these results on protein binding to the Mki67 promoter are consistent with earlier observations. In compilations of ChIP data, we noticed that the Mki67 gene can bind the DREAM/MuvB components p130, E2F4, and LIN9, as well as B-MYB and FOXM1 [17, 18, 29, 59]. In addition, in a screening experiment, it was shown that E2F4 can strongly bind the Mki67 gene [60]. E2F4 and E2F5, as components of DREAM, can interact with CDE sites, while DREAM attaches to CHR sites with its LIN54 component [39, 61] (Fig. 9).
Regulation of MKI67/Ki-67 expression during the cell cycle. Repression of transcription in G₀ and G₁ cells requires two DREAM complexes binding to one CDE and two CHR sites in the MKI67 promoter. One DREAM complex binds the downstream CHR site through the LIN54 subunit of the MuvB core complex. The second DREAM complex employs, in addition to a LIN54-CHR binding, complex formation of E2F4/5-DP heterodimers with the CDE site. In contrast to the direct interaction of DREAM complexes with the MKI67 promoter, RB does not directly control MKI67 transcription via binding to the gene. RB indirectly contributes to regulation through the CHR and CDE sites by influencing DREAM function. Once cells progress through the cell cycle, the p107/p130-E2F4/5-DP module dissociates from DREAM causing loss of repression. Instead, B-MYB and later FOXM1 sequentially bind to the MuvB core complex. Binding of B-MYB and FOXM1 through LIN54/ MuvB to CHR elements leads to transcriptional activation and expression of MKI67/Ki-67. Transcription of MKI67 starts in late G₁ phase and continues into mitosis with peak expression in G₂/M.
loop, as the downregulation of Ki-67 will lead to a further increase in p21 levels. Also, loss of Ki-67 expression leads to cell stress followed by p53/p21 activation. Furthermore, the model has to be extended, because in addition to G1/S also G2/M genes are affected by an increase in p21 levels and the resulting repression by DREAM complexes [34]. In addition to proteins such as p21, inhibition of CDKs can also be achieved by small molecule drugs. The CDK inhibitors Palbociclib, Ribociclib, and Abemaciclib are employed in cancer therapy, so far in the treatment of breast cancer. They can inhibit CDK4 and CDK6, leading to hypophosphorylated forms of RB, p107/RBL1, and p130/RBL2. Complex formation with the hypophosphorylated proteins then restores transcriptional repression by RB or DREAM [19, 64–66]. Results presented here suggest that CDK4/6 inhibition leads to MKI67 downregulation by DREAM. The finding that CDK4/6 inhibitor treatment affects Ki-67 expression prompted the question whether Ki-67 nevertheless remains a reliable parameter to monitor proliferation in a therapeutic setting. It was found that Ki-67 is also a valid marker after such treatments and, consistently, a recent study employed Ki-67 immunohistochemistry to assess patient response following treatment with Abemaciclib [12, 67]. Thus, downregulation of Ki-67 expression through the DREAM-dependent mechanism described here is consolidated by the CDK inhibitors Palbociclib, Ribociclib, and Abemaciclib. Further, as Ki-67 downregulation by CDK inhibitors is accompanied by downregulation of many DREAM targets leading to cell cycle arrest. This links CDK inhibitor function, Ki-67, and DREAM target regulation ultimately with therapeutic success. In consequence, Ki-67 is also a valid indicator for therapy outcome in a setting under CDK inhibitor treatment [19, 30]. In conclusion, we present mechanisms how MKI67 gene expression followed by Ki-67 protein synthesis is controlled during the cell cycle and upon induction of DNA damage, as well as upon p53 activation.

REFERENCES

1. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;33:13–20.
2. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
3. Gerdes J, Li L, Schluter C, Duchsow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–73.
4. Gerdes J, Lemke H, Baishc H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.
5. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14:8019–26.
6. Booth DG, Takagi M, Sanchez-Pulido L, Petfalski E, Vargiu G, Samejima K, et al. Ki-67 is a PPI-interacting protein that organises the mitotic chromosome periphery. Elife 2014;3:e01641.
7. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Nat Rev Cancer. 2013;13:585–95.
8. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
9. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Crit Rev Biochem Mol Biol. 2017;52:638–62.
10. Schmitz F, Korenjak M, Mannefeld M, Schmitt K, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.
11. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14:8019–26.
12. Booth DG, Takagi M, Sanchez-Pulido L, Petfalski E, Vargiu G, Samejima K, et al. Ki-67 is a PPI-interacting protein that organises the mitotic chromosome periphery. Elife 2014;3:e01641.
13. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Nat Rev Cancer. 2013;13:585–95.
14. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
15. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Nat Rev Cancer. 2013;13:585–95.
16. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
17. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Nat Rev Cancer. 2013;13:585–95.
18. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
19. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Nat Rev Cancer. 2013;13:585–95.
20. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
21. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Nat Rev Cancer. 2013;13:585–95.
22. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
23. Cuylen S, Blaukopf C, Politi AZ, Muller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Nat Rev Cancer. 2013;13:585–95.
24. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.
39. Müller GA, Stangner K, Schmitt T, Wintsche A,Engeland K. Timing of transcription during the cell cycle: protein complexes binding to E2F, E2F/CLE, CDE/CHR, or CHF promoter elements define early and late cell cycle gene expression. Onco-target. 2016;8:97736–48.

40. Qin XQ, Chittenden T, Livingston DM, Kaelin WG Jr. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 1995;25:53–64.

41. Tarasov KV, Tarasoya YS, Tam WL, Riordon DR, Elliott ST, Kania G, et al. B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS ONE. 2008;3:e2478.

42. Müller GA, Engeland K. DNA affinity purification: a pulldown assay for identifying and analyzing proteins binding to nucleic acids. Methods Mol Biol. 2012;67:81–90.

43. Fischer M, Quaaas M, Wintsche A, Müller GA, Engeland K. Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE/CHR sites and deregulated by HPV E7 protein. Nucleic Acids Res. 2014;42:163–80.

44. Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F. p53 downregulates the Fanconi anemia DNA repair pathway. Nat Commun. 2016;7:11091.

45. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol. 2000;20:3626–32.

46. Fischer M, Grundke I, Sohr S, Quaaas M, Hoffmann S, Knörr A, et al. p53 and cell cycle dependent transcription of kinesin family member 23 (KIF23) is controlled via a CHF promoter element bound by DREAM and MMB complexes. PLoS ONE. 2013;8:e63187.

47. Zheng N, Fraenkel E, Pabo CO, Pavletich NP. Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev. 1999;13:666–74.

48. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res. 1998;26:1135–43.

49. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1982;243:934–7.

50. Fischer M, Uxa S, Stanko C, Magin TM, Engeland K. Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway. Sci Rep. 2017;7:2603.

51. Enache OM, Rendo V, Abdusamad M, Lam D, Davison D, Pal S, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020;52:662–8.

52. Chestukhin A, Litovchik L, Rudich K, DeCaprio JA. Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism. Mol Cell Biol. 2002;22:453–68.

53. Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol. 1987;133:579–84.

54. Miller I, Lim M, Yang C, Tian C, Gookin S, Carter D, et al. K67 is graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24:1105–12.

55. Schmit F, Cremer S, Gubatze S. LIN54 is an essential core subunit of the DREAM/LINC complex that binds to the cdc2 promoter in a sequence-specific manner. FEBs J. 2009;276:5703-16.

56. Marceau AH, Felthousen JG, Goetsch PD, Iness AN, Lee HW, Tripathi SM, et al. Structural basis for LIN54 recognition of CHR elements in cell cycle-regulated promoters. Nat Commun. 2016;7:12301.

57. Zhang Z, Tu K, Liu F, Liang M, Yu K, Wang Y, et al. FoxM1 promotes the migration of ovarian cancer cell through KRT5 and KRT7. Gene. 2020;757:144947.

58. Tschoik K, Conery AR, Litovchik L, DeCaprio JA, Settleman J, Harlow E, et al. A kinase shRNA screen links LAT52 and the pRB tumor suppressor. Genes Dev. 2011;25:814–30.

59. Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TPS3, DREAM, MMB-FoxM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res. 2016;44:6070–86.

60. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev. 2002;16:245–56.

61. Gulley KZ, Liban TJ, Felthousen JG, Ramanan P, Litovchik L, Rubin SM. Structural mechanisms of DREAM complex assembly and regulation. Genes Dev. 2015;29:961–74.

62. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:479–58.

63. Wang MJ, Pei DS, Qian GW, Yin XX, Cheng Q, Li LT, et al. p53 regulates Ki-67 promoter activity through p53– and Sp1-dependent manner in HeLa cells. Tumour Biol. 2011;32:905–12.

64. Beijersbergen RL, Carlee L, Kerkhoven RM, Bernards R. Regulation of the retinoblastoma protein-related 107 by G1 cyclin complexes. Genes Dev. 1995;9:1340–53.

65. Bruce JL, Hurford RK Jr., Classon M, Koh J, Dyson N. Requirements for cell cycle arrest by p16INK4a. Mol. Cell. 2000;6:737–42.

66. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417–30.

67. Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, et al. Potent cell-cycle inhibition and upregulation of immune response with Abemaciclib and Anastrozole in neoadjuvant Study in HR(+)/HER2(-) breast cancer. Clin Cancer Res. 2020;26:656–80.

ACKNOWLEDGEMENTS

We are indebted to Kathrin Jäger at the core unit for performing flow cytometry, to Bert Vogelstein for the kind gift of HCT116 cell lines, Roger Watson for generously providing the anti-B-MYB monoclonal antibody, and Christine E Engeland for critical reading of the manuscript.

AUTHOR CONTRIBUTIONS

KE and GAM conceived and supervised the study. SU, PC-B, RK, and KS performed the experiments. KE and SU, with the help of GAM, wrote the manuscript. All authors read and approved the final manuscript.

FUNDING

This work was supported by a scholarship from the Studienstiftung des deutschen Volkes (German Academic Scholarship Foundation), the Helga Reifert-Preis for Experimentelle Krebforschung, and a fellowship from the Christiane Nüsslein-Volhard Foundation (all three to SU), and was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under project numbers 277046125 (to GAM) and 424870812 (to KE). Open Access funding enabled and organized by Project ORCID.

ETHICS STATEMENT

The study did not require ethical approval.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1038/s41418-021-00823-x.

Correspondence and requests for materials should be addressed to K.E.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021

Cell Death & Differentiation (2021) 28:3357 – 3370

Springer Nature Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021